EE423 Cost-Effectiveness of Vaccinating Adults ≥65 Years and at-Risk Individuals 18-64 Years With the 20-Valent Pneumococcal Conjugate Vaccine Versus Currently Recommended Vaccine Regimens in Sweden
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.669
https://www.valueinhealthjournal.com/article/S1098-3015(22)02873-X/fulltext
Title :
EE423 Cost-Effectiveness of Vaccinating Adults ≥65 Years and at-Risk Individuals 18-64 Years With the 20-Valent Pneumococcal Conjugate Vaccine Versus Currently Recommended Vaccine Regimens in Sweden
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02873-X&doi=10.1016/j.jval.2022.09.669
First page :
Section Title :
Open access? :
No
Section Order :
10201